Whereas selective mGluR1 antagonists such as EMQMCM or AIDA were ineffective in a rodent model of L-DOPA-induced dyskinesias [233], several preclinical studies have suggested such a potential for mGluR5 blockade. This evidence concerns the gene GRM5 and drug-induced dyskinesia.